Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients.

Yildiz, EDİBE; Ozkan, Melis; Bektas, Gonca; Uzunhan, Tugce; Aydinli, Nur; Caliskan, Mine; Ozmen, Meral

doi:10.1007/s00381-017-3586-8

Lacosamide treatment of childhood refractory focal epilepsy: the first reported side effect in paediatric patients.

Yildiz E., Ozkan M. U., Bektas G., Uzunhan T. A., Aydinli N., Caliskan M., ...Daha Fazla

Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, cilt.33, sa.11, ss.2023-2027, 2017 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 33 Sayı: 11
Basım Tarihi: 2017
Doi Numarası: 10.1007/s00381-017-3586-8
Dergi Adı: Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.2023-2027
Anahtar Kelimeler: Lacosamide, Status epilepticus, Childhood, Focal epilepsy, ADJUNCTIVE THERAPY, EFFICACY, CHILDREN, SAFETY, TOLERABILITY
İstanbul Üniversitesi Adresli: Evet

Özet

Lacosamide (LCM) is an effective antiepileptic drug (AED) approved for the treatment of focal epilepsy in both children and adults. The aim of this observational study was to review our centre's experience with LCM and to characterise its efficacy and tolerability as an adjunct therapy in children with refractory focal epilepsy.